Global

Whatever the final outcome of Brexit, investing in supporting advocacy communities will be an important element of maintaining trusted relationships with patient groups and stakeholders in the UK and the EU, write Nick Hicks and Tamsin Rose.

This article discusses three key considerations a manufacturer should either understand or seek a consulting partner to guide them through a commercialization plan.

The Commission’s gestures toward enacting formal standards to digitize health records are masking wider policy gaps.

Parliament throws wrench in Commission’s plan to regulate HTA.

Anjum Swaroop, Vice President and Head of IP at Dr. Reddy's, talks to Pharm Exec about her journey with the company and about what the future holds for this major US generics player.

Michael W. Magdycz share some of the lessons he's learned directing alliances spanning a range of countries and products.

Jin Zhang provides an overview of China's major bispecific antibody developers.

Disparities in income levels in China continue to drive far-reaching differences in how poorer and richer cancer patients are treated, with recent data suggesting that the differences in access to treatment lead to different outcomes for poorer patients. Peter De Richter reports.

What will come out of Austria’s shakeup of European pharma rules?

The call to reduce market entry times for life-saving new drug therapies is becoming more urgent. What constitutes best practice in managing translations in today’s regulatory affairs environment? Nancy Pollini reports.

In the face of booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports.

Tyrosine-kinase inhibitors (TKIs) are gradually becoming the most popular option for lung cancer treatment in China. Jin Zhang reports.

A recently announced collaboration between EUnetHTA, WHO, and ISPOR brings home the fact that there is still no real agreement on a definition of HTA, writes Reflector.

Maude Schmidt and Giovanni Saldutti look at the intergovernmental initiatives involving joint price negotiations developed across Europe as the Beneluxa Initiative on Pharmaceutical Policy to explore the outcomes and implications from these alliances.

Record capital flows across global public and private markets has opened up new channels of investment in early-stage and novel science.

In an attempt to reduce high drug prices and improve its medical insurance coverage, China has initiated a series of new moves, including the recent zero import tax on a range of anticancer drugs. Jin Zhang reports.

Over the last decade, Spain has seen a significant growth in venture-capital investment in the life sciences. We explore the driving forces.

Research-based companies in Europe look as though they have lost one battle on preserving incentives for innovation – but the bigger war is only now getting underway, writes Reflector.

Artificial intelligence adoption by pharma companies in the UK demands a new, agile governance layer, write Tim Wright and Antony Bott.

With China predicted to account for 48% of the global diabetes population by 2045, Jin Zhang looks at how the country's domestic pharma companies are faring in this treatment area.

Global pharma companies and Japan can create a win-win situation through a new pricing mechanism, writes Nobuko Kobayashi.

Raman Sehgal talks to three industry leaders for their insights on the challenges faced across the life science sector and how the EMA needs to respond.

Filip Conic outlines the market-access approaches and commercial strategies to unlock the growth potential in the Southeastern and Eastern European region.